Fundamental Analysis of PALISADE BIO INC(NASDAQ:PALI) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to PALI. PALI was compared to 568 industry peers in the Biotechnology industry. The financial health of PALI is average, but there are quite some concerns on its profitability. PALI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PALI has reported negative net income.

In the past year PALI has reported a negative cash flow from operations.

In the past 5 years PALI always reported negative net income.

In the past 5 years PALI always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -150.65%, PALI is doing worse than 85.31% of the companies in the same industry.

PALI has a Return On Equity of -212.85%. This is in the lower half of the industry: PALI underperforms 69.03% of its industry peers.

		Industry Rank	Sector Rank
ROA	-150.65%
ROE	-212.85%
ROIC	N/A

ROA(3y)-130.24%

ROA(5y)-128.45%

ROE(3y)-194.79%

ROE(5y)-182.77%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PALI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PALI does not have a ROIC to compare to the WACC, probably because it is not profitable.

PALI has more shares outstanding than it did 1 year ago.

PALI has more shares outstanding than it did 5 years ago.

The debt/assets ratio for PALI is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -23.75, we must say that PALI is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -23.75, PALI is doing worse than 89.03% of the companies in the same industry.

There is no outstanding debt for PALI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-23.75

ROIC/WACCN/A

WACC11.68%

2.3 Liquidity

PALI has a Current Ratio of 3.31. This indicates that PALI is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 3.31, PALI is in line with its industry, outperforming 40.35% of the companies in the same industry.

A Quick Ratio of 3.31 indicates that PALI has no problem at all paying its short term obligations.

PALI has a Quick ratio (3.31) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.31
Quick Ratio	3.31

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

PALI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -122.42%.

PALI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

The Revenue has been decreasing by -0.78% on average over the past years.

EPS 1Y (TTM)-122.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%64.85%

Revenue 1Y (TTM)-100%

Revenue growth 3Y164.57%

Revenue growth 5Y-0.78%

Sales Q2Q%N/A

3.2 Future

PALI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.41% yearly.

The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad

EPS Next Y55.65%

EPS Next 2Y35.36%

EPS Next 3Y22.23%

EPS Next 5Y12.41%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PALI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PALI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PALI's earnings are expected to grow with 22.23% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.36%

EPS Next 3Y22.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PALI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PALISADE BIO INC

NASDAQ:PALI (12/18/2024, 10:43:58 AM)

1.78

-0.12 (-6.32%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.37M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-150.65%
ROE	-212.85%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.31
Quick Ratio	3.31
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-122.42%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y55.65%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3Y164.57%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PALISADE BIO INC (PALI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens